Last reviewed · How we verify
CHF6001 DPI
CHF6001 DPI is a dry powder inhaler formulation of a long-acting muscarinic antagonist.
CHF6001 DPI is a dry powder inhaler formulation of a long-acting muscarinic antagonist. Used for Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | CHF6001 DPI |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Long-acting muscarinic antagonist |
| Target | M3 muscarinic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
It works by relaxing the airway muscles to improve lung function in patients with chronic obstructive pulmonary disease (COPD). CHF6001 DPI is designed to provide sustained bronchodilation and improve symptoms in patients with COPD.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Cough
- Dysphonia
- Upper respiratory tract infection
Key clinical trials
- A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PHASE3)
- Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy (PHASE2)
- A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) (PHASE3)
- A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001 (PHASE2)
- Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study (PHASE1)
- Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers (PHASE1)
- Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects (PHASE1)
- Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF6001 DPI CI brief — competitive landscape report
- CHF6001 DPI updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI